Pliant Therapeutics (PLRX) Equity Ratio (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Equity Ratio data on file, last reported at 0.82 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.82, up 9.3% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.82 (up 9.3% YoY), and the FY2025 annual result was 0.8, up 5.03% from the prior year.
• Equity Ratio rose to 0.82 in Q1 2026 per PLRX's latest filing, from 0.8 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.94 in Q1 2023 and troughed at 0.72 in Q3 2025.
• A 5-year average of 0.84 and a median of 0.82 in 2026 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio increased 15.83% in 2023, then fell 17.16% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.89 in 2022, then climbed by 3.47% to 0.92 in 2023, then dropped by 17.16% to 0.77 in 2024, then climbed by 5.03% to 0.8 in 2025, then increased by 1.33% to 0.82 in 2026.
• Business Quant data shows PLRX's Equity Ratio at 0.82 in Q1 2026, 0.8 in Q4 2025, and 0.72 in Q3 2025.